What is Amgen Inc. (AMGN)?

Amgen Inc. (AMGN) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

What is the current price of AMGN?

The current price of AMGN is $449.78. Prices are updated in real time on Stocks360.

What is AMGN's price-to-earnings (PE) ratio?

AMGN's trailing twelve-month PE ratio is 27.73, based on current price and earnings per share data available on Stocks360.

What is AMGN's market capitalization?

AMGN's market capitalization is $243,165,460,960.00, placing it in the large-cap tier.

Does AMGN pay a dividend?

Yes. AMGN has a trailing twelve-month dividend yield of 0.02%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Amgen Inc. (AMGN)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - General

$449.78

Market Cap

$243.17B

PE (TTM)

27.73

EPS (TTM)

N/A

Dividend Yield

2.21%

Beta

0.41

Day Range

$439.70 – $454.66

52-wk Range

$288.00 – $454.66

Avg Volume

N/A

Volume

1.34M

Amgen Inc. (AMGN) is a publicly traded company in the Healthcare sector. Latest price: $449.78. Market cap $243.17B. Trailing PE 27.73. Dividend yield 2.21%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $292.09 2026-10-28 · $450.06 (+54.08%)

Earnings

Most Recent

Aug 4, 2026

EPS $6.29 vs est. $5.62

Beat by $0.67

Next Earnings

Nov 3, 2026

EPS estimate $5.79

Proprietary Signals

Signal snapshot temporarily unavailable.

About Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital rol…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	27.73×
P/S (TTM)	6.38×
P/B	20.78×
PEG	0.88×
P/FCF (TTM)	23.90×
EV / EBITDA	16.26×
EV / Sales	7.51×
Earnings Yield	3.60%
Free Cash Flow Yield	4.18%
Dividend Yield	2.21%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$286.48B
Revenue (TTM)	$38.13B
Net Income (TTM)	$8.75B
Free Cash Flow (TTM)	$12.44B
Net Debt	$43.31B
Working Capital	$9.46B
Gross Margin	72.65%
Operating Margin	33.18%
Net Margin	22.93%
Return on Equity	89.32%
Return on Invested Capital	14.22%